YOUAI

Youai Biotech is a clinical-stage biotechnology company based in Shenzhen, China, specializing in the development of universal, off-the-shelf cell therapies derived from induced pluripotent stem cells (iPSCs). The company's core technology platform focuses on the large-scale production of standardized Natural Killer (NK) cells, aiming to provide a more accessible alternative to personalized autologous treatments. By engineering these iPSC-derived NK cells with Chimeric Antigen Receptors (CARs), Youai Biotech targets a variety of hematological malignancies and solid tumors. The firm was founded by Dr. Li Lingsong, a prominent figure in stem cell research, and has secured significant backing from leading venture capital firms. Their mission is to revolutionize cancer immunotherapy through the delivery of high-quality, cost-effective, and universal cell products.